Track topics on Twitter Track topics that are important to you
On Tuesday, Elliott Management Corporation (“Elliott”) released a letter to the Board of Directors of athenahealth, Inc. regarding Elliott’s proposal to acquire athenahealth for $160 per share ...
GREENVILLE, N.C., April 2, 2018/PRNewswire/ -- Elliott Squiresis recognized by Continental Who's Who as a Pinnacle Lifetime Member in the field of Read more...
After Elliott Management sent a third letter to athenahealth urging it to consider the offer, the EHR vendor retorted with a statement of its own, noting it will take its time in evaluating the bid.
Investment firm Elliott Management has proposed acquiring Watertown, Mass.-based health IT vendor athenahealth in a deal worth nearly $7 billion.
In a letter to athenahealth’s board of directors, Elliott Management Partner Jesse Cohn makes his firm’s case for why the company would be better off as a private business.
STADA Arzneimittel AG 12.01.2018 / 15:21 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this...
Elliott makes $7B all-cash bid for Athenahealth nleider Mon, 05/07/2018 - 14:44 Teaser Media
Correction of a release from 12.01.2018, 15:21 CET/CEST - STADA Arzneimittel AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
STADA Arzneimittel AG 29.01.2018 / 15:04 Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this...
INDICLORHigh Purity Indium Chloride In-111 Sterile Solution
INDIUM IN 111OXYQUINOLINE SOLUTION
TECHNESCAN HDP Kit for the Preparation of Technetium Tc 99m Oxidronate
In the original version of this article, author Ryan Elliott's name was misspelled as Ryan Eliott. The correct spelling of the name is Ryan Elliott.
The original version of this article unfortunately contained a mistake in the author names. The co-author names should be David Meetze and Ronald Whicker Jr. instead of David Meetz and Ronald Wicker. ...
Worldwide tree mortality as induced by climate change presents a challenge to forest managers. To successfully manage vulnerable forests requires the capacity of regeneration to compensate for losses ...
Dr. Elliott Sherr and his collaborators at University of California, San Francisco (UCSF) are studying the genetic causes of disorders of cognition and epilepsy, in particular disorders of...
Work place related (lower) back pain in medical personnel is limiting to workability. Even though occupational prevention programs are increasingly established, data on the effectiveness ...
A multi-center, placebo controlled, double-blind trial comparing the efficacy and safety of 18 months of treatment with deferiprone versus placebo in patients with PKAN. This investigator...
The overarching goal of this research is to create a tool that could reduce suicide rates, increase delivery of efficacious suicide interventions, and decrease overall costs associated wit...
The purpose of this two phase study is to evaluate comprehension by people with acquired brain injury. The phase 1 portion of the study will examine comprehension of narrative paragraphs u...
FS-Elliott is a global leader in the engineering and manufacturing of oil-free, centrifugal air compressors with operations in over 90 countries. Building on a 50-year tradition o...
DAVID Corporation, a pioneer in the alternative-risk market, has been providing business-improving services and process-automating software for more than a quarter of century. DAV...
We have published hundreds of David Elliott news stories on BioPortfolio along with dozens of David Elliott Clinical Trials and PubMed Articles about David Elliott for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of David Elliott Companies in our database. You can also find out about relevant David Elliott Drugs and Medications on this site too.